1-6 of 6
Howard Burris
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A First-in-Human Phase I Study to Evaluate the ERK1/2 Inhibitor GDC-0994 in Patients with Advanced Solid Tumors

Andrea Varga, Jean-Charles Soria, Antoine Hollebecque, Patricia LoRusso, Johanna Bendell, Shih-Min A. Huang, Marie-Claire Wagle, Kwame Okrah, Lichuan Liu, Elaine Murray, Sandra M. Sanabria-Bohorquez, Michael Tagen, Hatem Dokainish, Lars Mueller, Howard Burris
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (6): 1229–1236.
https://doi.org/10.1158/1078-0432.CCR-19-2574
Published: 13 March 2020
View article titled, A First-in-Human Phase I Study to Evaluate the ERK1/2 Inhibitor GDC-0994 in Patients with Advanced Solid Tumors
Open the PDF for A First-in-Human Phase I Study to Evaluate the ERK1/2 Inhibitor GDC-0994 in Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors

Kyung Hae Jung, Patricia LoRusso, Howard Burris, Michael Gordon, Yung-Jue Bang, Matthew D. Hellmann, Andrés Cervantes, Maria Ochoa de Olza, Aurelien Marabelle, F. Stephen Hodi, Myung-Ju Ahn, Leisha A. Emens, Fabrice Barlesi, Omid Hamid, Emiliano Calvo, David McDermott, Hatem Soliman, Ina Rhee, Ray Lin, Tony Pourmohamad, Julia Suchomel, Amy Tsuhako, Kari Morrissey, Sami Mahrus, Roland Morley, Andrea Pirzkall, S. Lindsey Davis
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (11): 3220–3228.
https://doi.org/10.1158/1078-0432.CCR-18-2740
Published: 03 June 2019
View article titled, Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors
Open the PDF for Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors in another window
Journal Articles

Histone Deacetylase Inhibitor Panobinostat Induces Clinical Responses with Associated Alterations in Gene Expression Profiles in Cutaneous T-Cell Lymphoma

Leigh Ellis, Yan Pan, Gordon K. Smyth, Daniel J. George, Chris McCormack, Roxanne Williams-Truax, Monica Mita, Joachim Beck, Howard Burris, Gail Ryan, Peter Atadja, Dale Butterfoss, Margaret Dugan, Kenneth Culver, Ricky W. Johnstone, H. Miles Prince
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (14): 4500–4510.
https://doi.org/10.1158/1078-0432.CCR-07-4262
Published: 15 July 2008
View article titled, Histone Deacetylase Inhibitor Panobinostat Induces Clinical Responses with Associated Alterations in Gene Expression Profiles in Cutaneous T-Cell Lymphoma
Open the PDF for Histone Deacetylase Inhibitor Panobinostat Induces Clinical Responses with Associated Alterations in Gene Expression Profiles in Cutaneous T-Cell Lymphoma in another window
Includes: Supplementary data
Journal Articles

A Phase 1 Escalating Single-Dose and Weekly Fixed-Dose Study of Cetuximab: Pharmacokinetic and Pharmacodynamic Rationale for Dosing

Paula M. Fracasso, Howard Burris, III, Matthew A. Arquette, Ramaswamy Govindan, Feng Gao, Lisa P. Wright, Sherry A. Goodner, F. Anthony Greco, Suzanne F. Jones, Noel Willcut, Catherine Chodkiewicz, Amit Pathak, Gregory M. Springett, George R. Simon, Daniel M. Sullivan, Raphaël Marcelpoil, Shelley D. Mayfield, David Mauro, Christopher R. Garrett
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (3): 986–993.
https://doi.org/10.1158/1078-0432.CCR-06-1542
Published: 08 February 2007
View article titled, A Phase 1 Escalating Single-Dose and Weekly Fixed-Dose Study of Cetuximab: Pharmacokinetic and Pharmacodynamic Rationale for Dosing
Open the PDF for A Phase 1 Escalating Single-Dose and Weekly Fixed-Dose Study of Cetuximab: Pharmacokinetic and Pharmacodynamic Rationale for Dosing in another window
Journal Articles

A Phase I and Pharmacokinetic Study of 1843U89, a Noncompetitive Inhibitor of Thymidylate Synthase, in Patients with Advanced Solid Malignancies

Garry Schwartz, Thomas R. Johnson, Andrew Goetz, Howard Burris, Leslie Smetzer, Thomas Lampkin, Jeffrey Sailstad, John A. Hohneker, Daniel D. Von Hoff, Eric K. Rowinsky
Journal: Clinical Cancer Research
Clin Cancer Res (2001) 7 (7): 1901–1911.
Published: 01 July 2001
View article titled, A Phase I and Pharmacokinetic Study of 1843U89, a Noncompetitive Inhibitor of Thymidylate Synthase, in Patients with Advanced Solid Malignancies
Open the PDF for A Phase I and Pharmacokinetic Study of 1843U89, a Noncompetitive Inhibitor of Thymidylate Synthase, in Patients with Advanced Solid Malignancies in another window
Journal Articles

A Comparison of Clinical Pharmacodynamics of Different Administration Schedules of Oral Topotecan (Hycamtin)

Cees J. H. Gerrits, Jan H. M. Schellens, Howard Burris, John R. Eckardt, Andre S. T. Planting, Maria E. L. van der Burg, Gail I. Rodriguez, Walter J. Loos, Vera van Beurden, Ian Hudson, Daniel D. Von Hoff, Jaap Verweij
Journal: Clinical Cancer Research
Clin Cancer Res (1999) 5 (1): 69–75.
Published: 01 January 1999
View article titled, A Comparison of Clinical Pharmacodynamics of Different Administration Schedules of Oral Topotecan (Hycamtin)
Open the PDF for A Comparison of Clinical Pharmacodynamics of Different Administration Schedules of Oral Topotecan (Hycamtin) in another window